© Florida Institue for Clinical Research | Privacy Policy
Website by 
COPD (TRITON)
Chiesi 06 CLI-05993AA3-06
The primary purpose of the Triton study is to see how safe the study drug is and how well it works to control the symptoms of COPD. The goals of the study are improving lung function, reducing moderate and severe COPD exacerbations, and reduce inflammation. The drug being researched in the TRITON study combines an ICS with drugs from both the LAMA and LABA groups.
To join the Triton study you must satisfy the following requirements:
- Be at least 40 years of age
- Have COPD and chronic bronchitis with current symptoms
- Be a current or former smoker who quit 6 or more months before entering the study
- Have had a COPD exacerbation in the past 12 months that required hospitalization or oral/injected corticosteroids and antibiotics
- Be on inhaled maintenance triple therapy for their COPD for at least 12 months
The study will last 55 weeks and involve 12 visits to the study center.